Allogeneic γδT Cells in Glioblastoma

This first-in-human clinical study aims to evaluate the safety and feasibility of locally delivered, allogeneic γδ T cells (genetically edited with ARIH1 and BCL11b knockout, designated ABOUT γδT cells) in patients with glioblastoma multiforme (GBM). The engineered effector cells are delivered via localized administration to selectively target and eliminate residual GBM cells. ABOUT: ARIH1 and BCL11b knockOUT γδ T cells.

NCT Number	NCT07144735
Lead Sponsor	Peking University Third Hospital Collaborators: Peking University, Changping Laboratory
Conditions	Glioblastoma (GBM), Glioblastoma Multiforme (GBM)
Enrollment	18 participants
Start Date	2025-04-01
Primary Completion	2027-12 (estimated)
Study Completion	2030-12 (estimated)
Updated on ClinicalTrials.gov	2025-08-27